<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-153034" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>CART Cell Therapy Toxicity</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shaikh</surname>
            <given-names>Soorih</given-names>
          </name>
          <aff>Dow University of Health Sciences</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shaikh</surname>
            <given-names>Hira</given-names>
          </name>
          <aff>University of Cincinnati Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Soorih Shaikh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hira Shaikh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>19</day>
          <month>4</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-153034.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Chimeric antigen receptor-T (CAR-T) cell therapy is an evolving treatment entity used to treat relapsed/refractory cancers. It involves genetically modifying autologous or allogeneic T cells to express Chimeric Antigen Receptor (CAR) proteins that target specific cancer cells. Despite promising outcomes, these cells attack normal tissue cells expressing similar proteins on their surfaces. This cross-reactivity results in adverse events (AEs), leading to substantial mortality and morbidity. This activity reviews the evaluation and treatment of CAR-T toxicity and highlights the role of interprofessional teams in evaluating and treating patients with these AEs.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the most common adverse events associated with CAR-T cell therapy.</p></list-item><list-item><p>Describe the pathophysiology for developing CAR-T AEs, such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).</p></list-item><list-item><p>Summarize management for CRS and ICANS.</p></list-item><list-item><p>Explain the importance of a multidisciplinary team approach to prevent morbidity and mortality of CAR-T-related toxicities.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=153034&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=153034">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-153034.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Chimeric antigen receptor-T (CAR-T) cell therapy is a type of genetically modified immunotherapy that is directed at cancer&#x000a0;cells. The method involves&#x000a0;using an individual's own T-cells&#x000a0;(or donor cells in allogeneic CART), transduced with gene encodes&#x000a0;<italic toggle="yes">ex vivo,&#x000a0;</italic>then introduced to the patient.<xref ref-type="bibr" rid="article-153034.r1">[1]</xref>&#x000a0;CAR-T has changed the treatment paradigm for&#x000a0;hematological malignancies, such as B-cell lymphomas and multiple myeloma, and continues to be a promising approach for many other malignancies, including solid tumors.<xref ref-type="bibr" rid="article-153034.r2">[2]</xref><xref ref-type="bibr" rid="article-153034.r3">[3]</xref><xref ref-type="bibr" rid="article-153034.r4">[4]</xref><xref ref-type="bibr" rid="article-153034.r5">[5]</xref></p>
        <p>Clusters of differentiation-19 (CD-19), a B cell surface marker, -directed CAR-T cells show encouraging outcomes in a variety of malignancies, including pediatric and B-cell acute lymphocytic leukemia (ALL), non-Hodgkin lymphoma (NHL), and chronic lymphocytic leukemia (CLL). The first approved CAR-T therapy&#x000a0;targeting CD-19, tisagenlecleucel (tisa-cel, ELIANA), was initially approved by the Food and Drug Administration (FDA) for patients with ALL in 2017,&#x000a0;and later diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma (JULIET).<xref ref-type="bibr" rid="article-153034.r6">[6]</xref><xref ref-type="bibr" rid="article-153034.r7">[7]</xref><xref ref-type="bibr" rid="article-153034.r8">[8]</xref>&#x000a0;Around the same time, axicabtagene ciloleucel (axi-cel, ZUMA-1) gained approval for relapsed/refractory (R/R) DLBCL and later for R/R follicular lymphoma.<xref ref-type="bibr" rid="article-153034.r9">[9]</xref><xref ref-type="bibr" rid="article-153034.r10">[10]</xref>&#x000a0;</p>
        <p>Since then, more agents such as lisocabtagene maraleucel&#x000a0;(liso-cel) have made their way onto the market, demonstrating better tolerance.<xref ref-type="bibr" rid="article-153034.r11">[11]</xref>&#x000a0;Later, brexucabtagene autoleucel was approved for R/R mantle cell lymphoma (MCL).<xref ref-type="bibr" rid="article-153034.r12">[12]</xref>&#x000a0;More recently, anti-B-cell Maturation Antigen (BCMA) CAR-T, idecabtagene vicleucel (ide-cel, KarMMa), and ciltacabtagene autoleucel (cilta-cel, CARTITUDE-1) have been approved for R/R&#x000a0;multiple myeloma.<xref ref-type="bibr" rid="article-153034.r3">[3]</xref><xref ref-type="bibr" rid="article-153034.r4">[4]</xref></p>
        <p>Despite the current success rate of CAR-T therapy, it comes with the caveat of significant toxicities. The most common adverse events (AEs) of CAR-T therapy, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), remain barriers to the use of CAR-T cell therapy. Other AEs,&#x000a0;such as cytopenia,s, infections, tumor lysis syndrome (TLS), acute anaphylaxis, etc., are also&#x000a0;challenging.<xref ref-type="bibr" rid="article-153034.r13">[13]</xref>&#x000a0;Now that cellular therapy is making its way to earlier lines of the treatment paradigm, these challenges have become even more relevant.<xref ref-type="bibr" rid="article-153034.r14">[14]</xref><xref ref-type="bibr" rid="article-153034.r15">[15]</xref></p>
      </sec>
      <sec id="article-153034.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The exact mechanism of CRS is not well&#x000a0;understood. CRS&#x000a0;is a systemic inflammatory response that occurs during the&#x000a0;CAR-T activation and expansion in the human body.<xref ref-type="bibr" rid="article-153034.r16">[16]</xref>&#x000a0;It is thought to be related to the cytokines secreted&#x000a0;during the tumor and immune effector cell interaction, including tumor necrosis factor-alpha (TNF-&#x003b1;) and interferon-gamma (IFN-&#x003b3;), which then&#x000a0;activate monocytes and macrophages to release&#x000a0;cytokines such as&#x000a0;interleukin-1 (IL-1), and IL-6.<xref ref-type="bibr" rid="article-153034.r17">[17]</xref>&#x000a0;</p>
        <p>ICANS is thought to be related to myeloid cell activation, including granulocyte-macrophage colony-stimulating factor (GM-CSF) mediated stimulation of monocytes after CAR-T and&#x000a0;monocyte-derived IL-1 and IL-6.&#x000a0;<xref ref-type="bibr" rid="article-153034.r18">[18]</xref><xref ref-type="bibr" rid="article-153034.r19">[19]</xref></p>
        <p>The costimulatory domain is a component of CAR-T necessary for T cell activation and expansion of the CAR-T cells.<xref ref-type="bibr" rid="article-153034.r20">[20]</xref>&#x000a0;CAR-T therapies that activate 4-1BB&#x000a0;(tisa-cel, liso-cel) costimulatory domain instead of CD28 (axi-cel) have exhibited slower expansion, thus prolonging the persistence of CAR-T cells and later CRS onset.<xref ref-type="bibr" rid="article-153034.r21">[21]</xref><xref ref-type="bibr" rid="article-153034.r22">[22]</xref>&#x000a0;While this has assisted in bringing these therapies outpatient, logistics, reimbursement,&#x000a0;and managing CAR-T therapy-related AEs are the major challenges healthcare providers face.<xref ref-type="bibr" rid="article-153034.r23">[23]</xref></p>
      </sec>
      <sec id="article-153034.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>CAR-T-related toxicity occurs with varying frequency depending on&#x000a0;factors discussed later. CRS&#x000a0;is the most common type of toxicity&#x000a0;associated with&#x000a0;CAR-T therapy, followed by ICANS.</p>
        <p>
<bold>Cytokine Release Syndrome (CRS)</bold>
</p>
        <p>CRS&#x000a0;is considered&#x000a0;a predominantly reversible complication of CAR-T therapy, with an incidence of occurrence in 42&#x000a0;to 100% of the patients. It presents with&#x000a0;varying severity, with 0&#x000a0;to&#x000a0;46% of patients exhibiting features of severe CRS and&#x000a0;from 0&#x000a0;to 9.1% of cases progressing to fatal outcomes.<xref ref-type="bibr" rid="article-153034.r24">[24]</xref></p>
        <p>
<bold>Immune Effector Cell-Associated Neurotoxicity Syndrome&#x000a0;(ICANS)</bold>
</p>
        <p>Similar to CRS, ICANS presents in most patients after CAR-T infusions as a reversible complication. It occurs less frequently and is often delayed compared to CRS, with the incidence ranging between 3&#x000a0;and 64% and 0&#x000a0;to 54% of cases exhibiting signs of severe illness.<xref ref-type="bibr" rid="article-153034.r25">[25]</xref></p>
      </sec>
      <sec id="article-153034.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>
<bold>Cytokine Release Syndrome (CRS)</bold>
</p>
        <p>CRS is the most common type of toxicity following CAR-T therapy. It&#x000a0;is a multi-systemic inflammatory response&#x000a0;caused by cytokines released following the infusion of CAR-T cells that can lead to multiorgan dysfunction. The onset&#x000a0;of symptoms usually occurs during the first week after CAR-T cell infusion, with a typical duration of 7 to 8 days.<xref ref-type="bibr" rid="article-153034.r26">[26]</xref><xref ref-type="bibr" rid="article-153034.r27">[27]</xref>&#x000a0;</p>
        <p>Multiple risk factors for CRS include high disease burden, a high number of administered CAR-T cells, the high peak of CAR-T cell expansion, thrombocytopenia, endothelial activation before CAR-T infusion, and lymphodepletion therapy with fludarabine and cyclophosphamide.<xref ref-type="bibr" rid="article-153034.r27">[27]</xref>&#x000a0;</p>
        <p>Studies have suggested that disease characteristics such as tumor burden, Eastern Cooperative Oncology Group (ECOG) performance status, ferritin,&#x000a0;lactate dehydrogenase (LDH), and C reactive protein (CRP) levels prior to CAR-T can be used as predictors of the onset of CRS and ICANS, thus guiding the outcomes&#x000a0;of CAR-T.<xref ref-type="bibr" rid="article-153034.r28">[28]</xref><xref ref-type="bibr" rid="article-153034.r28">[28]</xref></p>
        <p>
<bold>Pathophysiology</bold>
</p>
        <p>CRS is thought to be related to&#x000a0;the production&#x000a0;of inflammatory cytokines by CAR-T, e.g., TNF-a, IFN-&#x003b3;, IL-2, IL-8, IL-10, and GM-CSF following interaction with corresponding target cells.<xref ref-type="bibr" rid="article-153034.r17">[17]</xref>&#x000a0;Following that, inflammation recruits and provokes bystander immune cells, e.g., macrophages, monocytes, dendritic cells (DC), and other T cells. Eventually, it potentiates the immune response by releasing IL-1 and IL-6 as well as nitric oxide. This hyperactivated inflammatory response provokes the endothelium, which further releases IL-6. This destabilizes membrane stability, resulting in capillary membrane leakage, hemodynamic instability, and consumptive coagulopathy.</p>
        <p>
<bold>Clinical Features&#x000a0;</bold>
<italic toggle="yes">
<bold>&#x000a0;</bold>
</italic>
</p>
        <p>CRS typically presents with constitutional symptoms such as a fever, fatigue, myalgia, arthralgia, rigors, or anorexia. It can rapidly progress to&#x000a0;tachycardia, hypotension requiring vasopressors and intensive care unit (ICU) care, tachypnea, and hypoxia. Eventually, it can lead to coagulopathy, capillary leak, respiratory failure, shock, and multiple organ failure.</p>
        <p>&#x000a0;<bold>Immune Effector Cell-associated Neurotoxicity Syndrome&#x000a0;(ICANS)</bold></p>
        <p>It is a form of clinical and neuropsychiatric disease manifestation that occurs within days to 2-3 weeks following CAR-T therapy administration.<xref ref-type="bibr" rid="article-153034.r29">[29]</xref>&#x000a0;The risk factors for ICANS include the presence of CRS, pre-existing neurologic dysfunction, high disease burden, elevated&#x000a0;LDH, thrombocytopenia, elevated ferritin within 72 hours after CAR-T cell administration, chimeric antigen receptor&#x000a0;(CAR) design such as CD28 costimulatory domain, certain hinge, transmembrane CAR domains, and lymphodepletion therapy with fludarabine and cyclophosphamide.<xref ref-type="bibr" rid="article-153034.r29">[29]</xref></p>
        <p>
<bold>Pathophysiology</bold>
</p>
        <p>The pathophysiology behind ICANS is not well studied. Theories include CNS trafficking of CAR-T cells and endothelial disruption within the blood-brain barrier. Moreover, myeloid cell activation in the CNS with the secretion of IL-1 and IL-6 by monocytes, GM-CSF-mediated stimulation of monocytes after CART, elevated levels of IL-15, and N-methyl-D-aspartate (NMDA) receptor agonists (e.g., glutamate and quinolinic acid) have all been suggested to cause ICANS.<xref ref-type="bibr" rid="article-153034.r18">[18]</xref><xref ref-type="bibr" rid="article-153034.r19">[19]</xref></p>
        <p>
<bold>Cytopenias&#x000a0;</bold>
</p>
        <p>Cytopenias are very frequent following CAR-T cell therapy, the most common being neutropenia. They occur in about 20-40% of patients and can&#x000a0;last beyond&#x000a0;30 days after administration.<xref ref-type="bibr" rid="article-153034.r30">[30]</xref><xref ref-type="bibr" rid="article-153034.r31">[31]</xref>&#x000a0;According to a systematic analysis following CD-19 CAR-T therapy, the rates of&#x000a0;all grade anemia, thrombocytopenia, and neutropenia, were&#x000a0;65%, 55%, and 78%, respectively.&#x000a0;Age, gender, disease, number of prior lines of therapy, and&#x000a0;the target and costimulatory domain have been noted to influence the incidence&#x000a0;of cytopenias following&#x000a0;CAR-T therapy.<xref ref-type="bibr" rid="article-153034.r32">[32]</xref></p>
        <p>
<bold>Tumor Lysis Syndrome (TLS)</bold>
</p>
        <p>TLS can be a life-threatening condition leading to&#x000a0;arrhythmias and renal failure. It usually occurs due to cell depletion following chemotherapy but can occur&#x000a0;as a direct effect following CAR T-cell therapy.<xref ref-type="bibr" rid="article-153034.r33">[33]</xref>&#x000a0;It can be related to&#x000a0;elevated levels of serum creatinine and severe CRS.<xref ref-type="bibr" rid="article-153034.r34">[34]</xref></p>
        <p>
<bold>Anaphylaxis and Immunogenicity&#x000a0;</bold>
</p>
        <p>CAR-T cells involve the addition of non-human products that renders a risk for allergic reactions. Anaphylaxis is&#x000a0;rather uncommon and is reported only with repeated CAR-T infusions. Additionally, anti-murine antibodies against CD-19 have been detected prior to CAR-T cell infusion. Fully human-containing CAR-T cells are under clinical trials.<xref ref-type="bibr" rid="article-153034.r35">[35]</xref></p>
        <p>
<bold>Hypogammaglobulinema due to B-Cell Aplasia</bold>
</p>
        <p>B-cell aplasia with hypogammaglobulinemia is an expected AE&#x000a0;associated with CAR-T therapy.<xref ref-type="bibr" rid="article-153034.r36">[36]</xref><xref ref-type="bibr" rid="article-153034.r37">[37]</xref>&#x000a0;Hypogammaglobulinemia can be delayed and increases the risk of infections.<xref ref-type="bibr" rid="article-153034.r38">[38]</xref>&#x000a0;B-cell aplasia could last for up to 5 years, with longer aplasia usually being noticed after comprising 4-1BB as a costimulatory domain. Thus it can be used as a biomarker to assess CAR-T cell persistence.<xref ref-type="bibr" rid="article-153034.r39">[39]</xref><xref ref-type="bibr" rid="article-153034.r38">[38]</xref><xref ref-type="bibr" rid="article-153034.r40">[40]</xref></p>
        <p><bold>Infections</bold>&#x000a0;</p>
        <p>Multiple etiologies can explain&#x000a0;recurrent infections, including underlying disease, cytotoxic treatment, neutropenia, hypogammaglobinemia, treatment for CRS and ICANS, and the CAR-T itself. In addition, patients with an absolute neutrophil count (ANC) &#x0003c;500 cells/mm3&#x000a0;receiving higher doses of CAR-T therapy administration carry a higher risk than other patients.<xref ref-type="bibr" rid="article-153034.r30">[30]</xref></p>
        <p>&#x000a0;<bold>Hemophagocytic Lymphohistiocytosis (HLH)<bold>/Macrophage Activation Syndrome (MAS)</bold></bold></p>
        <p>Hemophagocytic lymphohistiocytosis (HLH) was reported in around 1% of patients receiving CAR-T cells.<xref ref-type="bibr" rid="article-153034.r41">[41]</xref>&#x000a0;It was unclear whether HLH/MAS represents the end point of CRS until&#x000a0;the ASTCT grading guidelines excluded HLH/MAS from the definition of CRS, and then the diagnostic criteria were identified (see table below).<xref ref-type="bibr" rid="article-153034.r41">[41]</xref></p>
        <table-wrap id="article-153034.table0" position="float" orientation="portrait">
          <table>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>Diagnostic Criteria of Hemophagocytic Lymphohistiocytosis (HLH)/Macrophage Activation Syndrome (MAS) [</bold><bold>adapted from criteria proposed by the CARTOX Working Group]</bold></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p>Ferritin &#x0003e;10,000 ng/ml during CRS&#x000a0;</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p>And two of the following: &#x000a0;Grade 3 liver toxicity (increase in levels of bilirubin, aspartate aminotransferase, or alanine aminotransferase) &#x000a0;Grade 3 kidney toxicity (oliguria or increase in serum creatinine) &#x000a0;Grade 3 pulmonary edema &#x000a0;Hemophagocytosis in the bone marrow or other organs&#x000a0;</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>
<bold>Secondary Malignancies</bold>
</p>
        <p>Secondary malignancies after CAR-T are primarily related to lymphodepletion chemotherapy, including myelodysplastic syndrome, acute myeloid leukemia, etc.<xref ref-type="bibr" rid="article-153034.r42">[42]</xref><xref ref-type="bibr" rid="article-153034.r43">[43]</xref></p>
        <p>&#x000a0;<bold>Graft-Versus-Host Disease (GVHD)</bold></p>
        <p>Patients receiving allogeneic CAR-T cells from donors carry a risk of developing mild acute GVHD or slow worsening of previously existing chronic GVHD, though this has only rarely been reported.<xref ref-type="bibr" rid="article-153034.r34">[34]</xref><xref ref-type="bibr" rid="article-153034.r44">[44]</xref></p>
      </sec>
      <sec id="article-153034.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Healthcare professionals caring for patients receiving commercial CAR-T products must complete product-specific Risk Evaluation and Mitigation Strategy (REMS) training.<xref ref-type="bibr" rid="article-153034.r45">[45]</xref><xref ref-type="bibr" rid="article-153034.r46">[46]</xref><xref ref-type="bibr" rid="article-153034.r47">[47]</xref>&#x000a0;Nurses caring for these patients are educated to recognize CAR-T AEs, especially CRS and ICANS.<xref ref-type="bibr" rid="article-153034.r46">[46]</xref>&#x000a0;</p>
        <p>Every CAR-T center has institutional guidelines&#x000a0;to evaluate the patients for related toxicities, depending on whether the CAR-T product was infused in an&#x000a0;inpatient or outpatient setting. Generally, in an outpatient setting, patients are evaluated once daily for both CRS and ICANS-related features for at least 14 days and up to 30 days post-infusion. If the CAR-T therapy is&#x000a0;administered inpatient, vitals are typically assessed every 4 hours; the ICE score is at least once a&#x000a0;day, with a daily comprehensive&#x000a0;physical exam and blood work including complete blood count (CBC) and complete metabolic panel (CMP).<xref ref-type="bibr" rid="article-153034.r41">[41]</xref>&#x000a0;</p>
        <p>If a patient is admitted with an AE such as CRS, vital signs are checked more frequently, ideally every 2-4 hours, immune effector cell-associated encephalopathy (ICE) score is evaluated at least once&#x000a0;a day and up to every 8 hours, and blood work including CBC, CMP, and other relevant tests are done once to twice daily.<xref ref-type="bibr" rid="article-153034.r41">[41]</xref><xref ref-type="bibr" rid="article-153034.r48">[48]</xref></p>
        <p>Most centers alert neurology service for a neurological evaluation of the patient before the CAR-T administration. However, in case of a suspected or confirmed ICANS-related toxicity, a neurological exam is performed at least 4-6 hourly or more frequently if a decline in the neurological status is noted.<xref ref-type="bibr" rid="article-153034.r49">[49]</xref>&#x000a0;Further neurological investigations, including neuroimaging, electroencephalogram (EEG), etc., are performed if there is a concern for ICANS.<xref ref-type="bibr" rid="article-153034.r41">[41]</xref></p>
      </sec>
      <sec id="article-153034.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Toxicities related to CAR-T cell therapy are diverse and still poorly understood.&#x000a0;The&#x000a0;evaluation&#x000a0;of CAR-T-associated toxicities and their severity is based on clinical symptoms and signs, which are further aided by laboratory biomarkers and/or radiological findings.</p>
        <p><bold>CRS</bold>: It is a clinical diagnosis and usually presents with varying degrees of fever, tachycardia, hypotension, hypoxia, nausea, vomiting, etc. The vital signs are assessed frequently, depending on the institutional policies, with most centers mandating reevaluation&#x000a0;every 4 hours for grades 1&#x000a0;and 2 and 1&#x000a0;to 2 hourly evaluations for grades 3&#x000a0;and 4 CRS.<xref ref-type="bibr" rid="article-153034.r41">[41]</xref><xref ref-type="bibr" rid="article-153034.r48">[48]</xref></p>
        <p>Useful laboratory evaluation for CRS involves performing a CBC, renal and liver function&#x000a0;test, coagulation profile, LDH, serum ferritin, IL-6, and CRP. These biomarkers are performed serially to determine the severity and response to the treatment. Some have also postulated checking IL-5, &#x000a0;IL-13, TNF-a, and IFN-&#x003b3; levels.<xref ref-type="bibr" rid="article-153034.r50">[50]</xref><xref ref-type="bibr" rid="article-153034.r51">[51]</xref>&#x000a0;</p>
        <p><bold>ICANS</bold>:&#x000a0;Like&#x000a0;CRS, ICANS is diagnosed based on clinical symptoms, including headache, impaired attention and consciousness, lethargy,&#x000a0;agitation, hallucinations, tremors, aphasia, encephalopathy, and seizures.<xref ref-type="bibr" rid="article-153034.r52">[52]</xref>&#x000a0;As discussed in detail below, the grading and surveillance of neurotoxicity are based on the ICE criteria (which has replaced the CARTOX-10&#x000a0;criteria to include more objectivity in the neurotoxicity grading).<xref ref-type="bibr" rid="article-153034.r50">[50]</xref><xref ref-type="bibr" rid="article-153034.r53">[53]</xref><xref ref-type="bibr" rid="article-153034.r28">[28]</xref></p>
        <p>Laboratory evaluation of ICANS includes biomarkers similar to CRS in addition to a lumbar puncture to analyze cerebrospinal fluid, neuroimaging, and EEG to determine the extent of damage from ICANS and rule out other organic factors and/or sinister causes, including but not limited to infections.<xref ref-type="bibr" rid="article-153034.r41">[41]</xref></p>
      </sec>
      <sec id="article-153034.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Here, we review the toxicities caused by CAR-T cell therapy and summarize the clinical findings, grades, and management of the most relevant adverse events associated with CAR-T cell therapy.</p>
        <p>The toxicity of CAR-T remains challenging. However, numerous safety measures have been implemented in clinical trials.<xref ref-type="bibr" rid="article-153034.r27">[27]</xref>&#x000a0;Standardized protocols need to be developed, including universal guidelines for managing CRS and ICANs and the safe administration of outpatient CAR-T therapy.<xref ref-type="bibr" rid="article-153034.r54">[54]</xref>&#x000a0;</p>
        <p>Management of CRS and ICANS requires frequent assessment and grading several times a day in addition to monitoring inflammatory markers such as ferritin and CRP. Aggressive supportive care is the cornerstone of managing&#x000a0;all patients experiencing CAR T-cell toxicities, with early intervention for hypotension and treatment of concurrent infections being essential.&#x000a0;IL-6 receptor blockade with tocilizumab remains the mainstay pharmacologic therapy for CRS, though indications for administration vary among centers. For FDA-approved&#x000a0;CAR-T cell products, REMS requires prompt&#x000a0;availability of at least two&#x000a0;doses of tocilizumab per&#x000a0;patient that can be administered within two&#x000a0;hours of CAR-T&#x000a0;infusion.<xref ref-type="bibr" rid="article-153034.r55">[55]</xref>&#x000a0;</p>
        <p>Corticosteroids should only be reserved for neurologic toxicities and CRS not responsive to tocilizumab. Pharmacologic management is complicated by the risk of immunosuppressive therapy abrogating the activity of the CAR-T cells.<xref ref-type="bibr" rid="article-153034.r56">[56]</xref>&#x000a0;Given the potential of corticosteroids to limit CAR-T cell proliferation and expansion, they should not be permitted starting on the first day of lymphodepletion chemotherapy, including&#x000a0;as antiemetics.<xref ref-type="bibr" rid="article-153034.r57">[57]</xref></p>
        <p>
<bold>Cytokine Release Syndrome (CRS)</bold>
</p>
        <p>Grading and management of CRS are derived&#x000a0;from the American Society for Transplantation and Cellular Therapy&#x000a0;(ASTCT) consensus guidelines for CRS grading.<xref ref-type="bibr" rid="article-153034.r28">[28]</xref><xref ref-type="bibr" rid="article-153034.r58">[58]</xref><xref ref-type="bibr" rid="article-153034.r59">[59]</xref>&#x000a0;</p>
        <table-wrap id="article-153034.table1" position="float" orientation="portrait">
          <table style="width: 800px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr style="height: 13px;">
                <td style="width: 37px; height: 13px;" rowspan="1" colspan="1">
<bold>Grade</bold>
</td>
                <td style="width: 360.769043px; height: 13px;" rowspan="1" colspan="1">
<bold>Clinical Presentation</bold>
</td>
                <td style="width: 584.230957px; height: 13px;" rowspan="1" colspan="1">
<bold>Management</bold>
</td>
              </tr>
              <tr style="height: 74px;">
                <td style="width: 37px; height: 74px;" rowspan="1" colspan="1">
<bold>&#x000a0;1</bold>
</td>
                <td style="width: 360.769043px; height: 74px;" rowspan="1" colspan="1">
<p>Symtpoms require symptomatic treatment only</p>
<list list-type="bullet"><list-item><p>Fever, nausea, fatigue, headache, myalgia, malaise, etc.,&#x000a0;but no hypotension or hypoxia.</p></list-item></list>
</td>
                <td style="width: 584.230957px; height: 74px;" rowspan="1" colspan="1">Supportive measures, including antipyretics, IV hydration, and infectious disease workup such as blood cultures and imaging as needed. If there is no improvement within&#x000a0;three days and no other differential diagnosis, consider tocilizumab as below.</td>
              </tr>
              <tr style="height: 119px;">
                <td style="width: 37px; height: 119px;" rowspan="1" colspan="1">
<bold>2</bold>
</td>
                <td style="width: 360.769043px; height: 119px;" rowspan="1" colspan="1">
<p>Symptoms require and respond to moderate&#x000a0;intervention</p>
<list list-type="bullet"><list-item><p>Fever (temperature &#x02265;38&#x000b0;C), and</p></list-item><list-item><p>Hypotension that doesn&#x02019;t require vasopressors and/or&#x000a0;</p></list-item><list-item><p>Hypoxia on low-flow oxygen (O2) &#x0003c;40% FiO2.</p></list-item></list>
</td>
                <td style="width: 584.230957px; height: 119px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Supportive measures, similar to grade 1&#x000a0;CRS, IV fluid boluses, supplemental oxygenation,&#x000a0;and</p></list-item><list-item><p>Tocilizumab 8 mg/kg once (maximum dose: 800 mg [based on CAR-T cell CRS dosing]). If there is no clinical improvement in the signs and symptoms of CRS after the first dose, repeat tocilizumab every 8 hours as needed. Limit to a maximum of 3 doses in a 24-hour period and a total of 4 doses.</p></list-item><list-item><p>Corticosteroids (dexamethasone 10 mg every 6 hours or methylprednisolone equivalent, that is 1 mg/kg twice daily) if no improvement within 24 hours of starting tocilizumab.</p></list-item></list>
</td>
              </tr>
              <tr style="height: 102px;">
                <td style="width: 37px; height: 102px;" rowspan="1" colspan="1">
<bold>3</bold>
</td>
                <td style="width: 360.769043px; height: 102px;" rowspan="1" colspan="1">
<p>Symptoms require and respond to aggressive intervention</p>
<list list-type="bullet"><list-item><p>Fever, and</p></list-item><list-item><p>Hypotension&#x000a0;that requires one&#x000a0;vasopressor and/or&#x000a0;</p></list-item><list-item><p>Hypoxia that&#x000a0;necessitates&#x000a0;high-flow O2 (high-flow nasal cannula, mask, non-invasive ventilation) &#x02265;40% FiO2.</p></list-item></list>
</td>
                <td style="width: 584.230957px; height: 102px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Supportive management similar to&#x000a0;CRS grade 1 and intensive care unit (ICU) management with vasopressor support and/or supplemental oxygen, and</p></list-item><list-item><p>Tocilizumab 8 mg/kg once (maximum dose: 800 mg [based on CAR-T cell CRS dosing]), plus&#x000a0;</p></list-item><list-item><p>Dexamethasone 10-20 mg IV every 6 h or methylprednisolone equivalent. &#x000a0;</p></list-item></list>
</td>
              </tr>
              <tr style="height: 87.956543px;">
                <td style="width: 37px; height: 87.956543px;" rowspan="1" colspan="1">
<bold>4</bold>
</td>
                <td style="width: 360.769043px; height: 87.956543px;" rowspan="1" colspan="1">
<p>Life-threatening symptoms</p>
<list list-type="bullet"><list-item><p>Fever, and</p></list-item><list-item><p>Hypotension that requires multiple vasopressors and/or</p></list-item><list-item><p>Hypoxia requiring positive pressure (e.g., CPAP, BiPAP, intubation, mechanical ventilation).</p></list-item></list>
</td>
                <td style="width: 584.230957px; height: 87.956543px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Supportive management similar to&#x000a0;CRS grade 1, ICU admission, vasopressor support, and/or supplemental O2 via the positive pressure method, and</p></list-item><list-item><p>Tocilizumab 8 mg/kg once (maximum dose: 800 mg [based on CAR-T&#x000a0;cell CRS dosing]), and</p></list-item><list-item><p>Methylprednisolone 1000 mg/day for three days.</p></list-item></list>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>
<bold>Immune Effector Cell-Associated Neurotoxicity Syndrome&#x000a0;(ICANS)</bold>
</p>
        <p>The grading and proposed management of ICANS are according to and adapted from the ASTCT consensus guidelines for ICANS grading.<xref ref-type="bibr" rid="article-153034.r28">[28]</xref><xref ref-type="bibr" rid="article-153034.r53">[53]</xref></p>
        <table-wrap id="article-153034.table2" position="float" orientation="portrait">
          <table style="width: 800px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr>
                <td style="width: 37px;" rowspan="1" colspan="1">
<bold>Grade</bold>
</td>
                <td style="width: 483.214722px;" rowspan="1" colspan="1">
<bold>Clinical presentation</bold>
</td>
                <td style="width: 464.785278px;" rowspan="1" colspan="1">
<bold>Management</bold>
</td>
              </tr>
              <tr>
                <td style="width: 37px;" rowspan="1" colspan="1">
<bold>1</bold>
</td>
                <td style="width: 483.214722px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Immune effector cell-associated encephalopathy (ICE) score 7-9.</p></list-item><list-item><p>Awakens&#x000a0;spontaneously.</p></list-item><list-item><p>No motor findings or seizure-like activity.</p></list-item><list-item><p>No signs of&#x000a0;increased intracranial pressure (ICP) or CNS edema.</p></list-item></list>
</td>
                <td style="width: 464.785278px;" rowspan="1" colspan="1">Supportive management with electroencephalogram (EEG), neuroimaging, and lumbar puncture. Add tocilizumab only if concurrent CRS.</td>
              </tr>
              <tr>
                <td style="width: 37px;" rowspan="1" colspan="1">
<bold>2</bold>
</td>
                <td style="width: 483.214722px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>ICE 3-6.</p></list-item><list-item><p>Awakens to a voice.</p></list-item><list-item><p>No motor findings or seizure-like activity.</p></list-item><list-item><p>No signs of increased ICP or CNS edema.</p></list-item></list>
</td>
                <td style="width: 464.785278px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Supportive management similar to&#x000a0;ICANS grade 1.</p></list-item><list-item><p>Consider dexamethasone 10 mg every 6 hours or methylprednisolone equivalent.</p></list-item></list>
</td>
              </tr>
              <tr>
                <td style="width: 37px;" rowspan="1" colspan="1">
<bold>3</bold>
</td>
                <td style="width: 483.214722px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>ICE 0-2.</p></list-item><list-item><p>Awakens only to tactile stimuli.</p></list-item><list-item><p>Usually presents with a seizure that resolves rapidly, with/without interventions.</p></list-item><list-item><p>There is usually focal or local edema on imaging.</p></list-item></list>
</td>
                <td style="width: 464.785278px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Supportive management similar to ICANS grade 1; consider transfer to ICU and airway protection.&#x000a0;</p></list-item><list-item><p>Dexamethasone 10-20 mg IV every 6 hours or methylprednisolone equivalent. If deterioration, increase steroids to that in grade 4.</p></list-item><list-item><p>Control seizures with antiepileptics and status with benzodiazepines.</p></list-item></list>
</td>
              </tr>
              <tr>
                <td style="width: 37px;" rowspan="1" colspan="1">
<bold>4</bold>
</td>
                <td style="width: 483.214722px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>ICE 0.</p></list-item><list-item><p>Unarousable, stuporous, or in a coma, or&#x000a0;requires vigorous stimuli to wake.</p></list-item><list-item><p>Usually presents with prolonged life-threatening seizures (&#x0003e;5 min) or repetitive clinical or electrical seizures without returning to baseline. Additionally may have deep focal weakness, i.e., hemiparesis or paraparesis.</p></list-item><list-item><p>Imaging shows diffuse cerebral edema. On physical examination, usually papilledema, decerebrate/decorticate posture, cranial nerve VI palsy, or Cushing&#x02019;s triad (bradycardia, hypertension, and abnormal breathing).</p></list-item></list>
</td>
                <td style="width: 464.785278px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Supportive management similar to ICANS grade 1, transfer to ICU, and airway protection, e.g., by intubation and mechanical ventilation.</p></list-item><list-item><p>High-dose methylprednisolone (1000 mg/day).</p></list-item><list-item><p>Control seizures with antiepileptics.</p></list-item><list-item><p>Lower elevated ICP with hyperventilation, hyperosmolar therapy, and/or neurosurgical intervention.</p></list-item><list-item><p>If refractory, discuss agents such as siltuximab or anakinra, as detailed below.</p></list-item></list>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>Immune effector cell-associated encephalopathy (ICE) assessment adapted from ASTCT grading consensus guidelines:<xref ref-type="bibr" rid="article-153034.r28">[28]</xref></p>
        <table-wrap id="article-153034.table3" position="float" orientation="portrait">
          <table border="6">
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>ICE Parameter</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p><bold>Task&#x000a0;</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p><bold>Scoring point</bold>&#x000a0;</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>Orientation&#x000a0;</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Orientation to the year, month, city, and hospital&#x000a0;</p>
</td>
                <td rowspan="1" colspan="1">
<p>4&#x000a0;</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>Naming &#x000a0;</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Ability to name three objects&#x000a0;</p>
</td>
                <td rowspan="1" colspan="1">
<p>3</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>Follow Commands&#x000a0;</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Ability to follow simple commands&#x000a0;</p>
</td>
                <td rowspan="1" colspan="1">
<p>1&#x000a0;</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>Writing Ability&#x000a0;</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Ability to write a standard sentence&#x000a0;</p>
</td>
                <td rowspan="1" colspan="1">
<p>1&#x000a0;</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<p><bold>Attention Ability</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Ability to count backward from 100 by 10s&#x000a0;</p>
</td>
                <td rowspan="1" colspan="1">
<p>1&#x000a0;&#x000a0;</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>
<bold>CRS and ICANS Refractory to the Above Treatment</bold>
</p>
        <p>If despite the use of tocilizumab and corticosteroids, patients with CRS and ICANS continue to worsen,&#x000a0;siltuximab, a monoclonal antibody, binds to &#x000a0;IL-6, thus preventing it from binding to the IL-6 receptors.<xref ref-type="bibr" rid="article-153034.r60">[60]</xref>&#x000a0;Another alternative is Anakinra, which is an IL-1 receptor that shows activity in&#x000a0;CRS and ICANS that is refractory to corticosteroids and tocilizumab.<xref ref-type="bibr" rid="article-153034.r61">[61]</xref>&#x000a0;Given that IL-1 precedes IL-6 production, it can be used to prevent CRS and ICANS. However, further studies are still under investigation.<xref ref-type="bibr" rid="article-153034.r62">[62]</xref></p>
        <p>
<bold>Cytopenias&#x000a0;</bold>
</p>
        <p>Mostly, cytopenias&#x000a0;resolve over time. Bone marrow biopsy is recommended in patients with&#x000a0;prolonged or delayed<italic toggle="yes">&#x000a0;</italic>cytopenias to evaluate for secondary bone marrow malignancy.<xref ref-type="bibr" rid="article-153034.r63">[63]</xref>&#x000a0;Anemia and thrombocytopenia are managed&#x000a0;through the replacement of erythrocytes and platelets. Granulocyte colony-stimulating factor (G-CSF) is used to manage neutropenia and should be strongly recommended in patients with prolonged neutropenia. Anecdotally, persistent refractory cytopenia after CAR-T has been treated by the infusion of autologous or allogeneic stem cells.<xref ref-type="bibr" rid="article-153034.r32">[32]</xref><xref ref-type="bibr" rid="article-153034.r63">[63]</xref></p>
        <p>
<bold>Tumor Lysis Syndrome</bold>
</p>
        <p>Management involves frequent hydration and&#x000a0;the use of uric acid-lowering agents (allopurinol,&#x000a0;rasburicase, and febuxostat) as per the standard guidelines for chemotherapy.<xref ref-type="bibr" rid="article-153034.r33">[33]</xref><xref ref-type="bibr" rid="article-153034.r64">[64]</xref></p>
        <p>
<bold>Hypogammaglobulinema Due to B-Cell Aplasia</bold>
</p>
        <p>Long-term follow-up is&#x000a0;essential to assess the need for&#x000a0;IgG replacement.<xref ref-type="bibr" rid="article-153034.r65">[65]</xref>&#x000a0;In pediatric patients, intravenous immunoglobulin (IVIG) replacement is typically given.<xref ref-type="bibr" rid="article-153034.r66">[66]</xref>&#x000a0;In adults, antibody-secreting CD19-negative cells resembling memory plasma cells that show&#x000a0;basic humoral immune function despite CAR-T cell treatment have&#x000a0;been noted. Hence, in adults, IVIG is usually given at IgG levels &#x02265; 400 mg/dl or in patients with severe or recurrent infections, usually at a dose of 400 to 600 mg/kg every 3 to 4 weeks.<xref ref-type="bibr" rid="article-153034.r66">[66]</xref><xref ref-type="bibr" rid="article-153034.r38">[38]</xref>&#x000a0;</p>
        <p><bold>Infections</bold>&#x000a0;</p>
        <p>Patients with fevers and neutropenia should have blood cultures drawn and broad-spectrum antibiotics initiated.<xref ref-type="bibr" rid="article-153034.r52">[52]</xref>&#x000a0;Antimicrobial prophylaxis is majorly extrapolated from that of hematopoietic stem cell transplants (HSCT). This includes antimicrobials, such as acyclovir or valacyclovir, for herpes simplex virus (HSV), and varicella zoster (VZV), starting prior to the conditioning chemotherapy continuing up to 1-year following CAR-T therapy.<xref ref-type="bibr" rid="article-153034.r30">[30]</xref><xref ref-type="bibr" rid="article-153034.r52">[52]</xref>&#x000a0;</p>
        <p>Trimethoprim-sulfamethoxazole or alternative agents are recommended for pneumocystis jirovecii (PJP) starting before&#x000a0;conditioning chemotherapy and is usually continued until CD4 reaches more than 200/ml.<xref ref-type="bibr" rid="article-153034.r30">[30]</xref><xref ref-type="bibr" rid="article-153034.r32">[32]</xref><xref ref-type="bibr" rid="article-153034.r52">[52]</xref>&#x000a0;Antifungal prophylaxis should be considered in those at high risk, such as prolonged steroid exposure, or in patients within patients with prolonged (&#x0003e;14 days) or severe (ANC &#x0003c;0.5&#x000a0;&#x000d7; 10/l) neutropenia.<xref ref-type="bibr" rid="article-153034.r30">[30]</xref></p>
        <p>
<bold>Hemophagocytic Lymphohistiocytosis</bold>
</p>
        <p>Treatment usually involves corticosteroids and tocilizumab if co-existent with CRS. In refractory cases or if independent of CRS, treatment with etoposide and intrathecal methotrexate or cytarabine has been suggested. Additionally, anakinra has also been proposed but needs further evaluation.<xref ref-type="bibr" rid="article-153034.r67">[67]</xref></p>
      </sec>
      <sec id="article-153034.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Differential diagnoses for CRS are mainly&#x000a0;related to its clinical manifestations and laboratory findings, such as&#x000a0;fever and/or hypoxia and hypotension, elevated CRP, ferritin, and IL-6 levels.<xref ref-type="bibr" rid="article-153034.r68">[68]</xref>&#x000a0;These include Infection/sepsis, anaphylactic reactions/shock, heart failure, thromboembolism, malignancy relapse/refractoriness, TLS, and HLH&#x000a0;unrelated to CAR-T toxicity.<xref ref-type="bibr" rid="article-153034.r69">[69]</xref><xref ref-type="bibr" rid="article-153034.r70">[70]</xref><xref ref-type="bibr" rid="article-153034.r71">[71]</xref>&#x000a0;</p>
        <p>These patients are usually required to undergo extensive evaluation and investigations to rule out other causes and often require empirical treatments until proven otherwise.</p>
        <p>ICANS can be frequently confused with uncommon viral infections, stroke, chemotherapy-related toxicity,&#x000a0;and&#x000a0;the CNS involvement of malignancy.<xref ref-type="bibr" rid="article-153034.r72">[72]</xref></p>
      </sec>
      <sec id="article-153034.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p><bold>CRS</bold>: It is a reversible complication, mostly&#x000a0;symptoms resolving within 2&#x000a0;to 6 weeks. Mortality can be observed in 0 to 9.1% of cases.<xref ref-type="bibr" rid="article-153034.r25">[25]</xref><xref ref-type="bibr" rid="article-153034.r24">[24]</xref>&#x000a0;However, the majority of&#x000a0;trials have reported &#x0003c;1% fatal outcomes.<xref ref-type="bibr" rid="article-153034.r28">[28]</xref></p>
        <p><bold>ICANS</bold>: A vast majority of cases of neurotoxicity associated with CART therapy show symptom resolution within 3-8 weeks.<xref ref-type="bibr" rid="article-153034.r73">[73]</xref><xref ref-type="bibr" rid="article-153034.r74">[74]</xref>&#x000a0;With early and aggressive management, even high-grade CRS is considered reversible.</p>
      </sec>
      <sec id="article-153034.s11" sec-type="Complications">
        <title>Complications</title>
        <p>While, in most instances, CAR-T complications are reversible, occasionally, they can lead to death or irreversible organ damage.<xref ref-type="bibr" rid="article-153034.r25">[25]</xref>&#x000a0;Neuropsychiatric AEs&#x000a0;such as anxiety, depression, or cognitive difficulty have been reported in long-term survivors of CAR-T, up to 37.5% in one study.<xref ref-type="bibr" rid="article-153034.r75">[75]</xref></p>
      </sec>
      <sec id="article-153034.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Frequent monitoring, clear instructions for patients and caregivers, and a robust on-call system are essential post-CAR-T. Patients and caregivers should be provided with after-hours contact information, clear instructions for monitoring symptoms and vital signs, and when to present to the hospital.<xref ref-type="bibr" rid="article-153034.r57">[57]</xref>&#x000a0;</p>
        <p>Patients need to&#x000a0;be provided with a product-specific wallet card identifying their reception of&#x000a0;a CAR T-cell product and giving information about the managing oncologist. They&#x000a0;will need to show their wallet card if and when&#x000a0;they present for evaluation of&#x000a0;symptoms, especially if they arrive at a hospital or emergency department (ED) outside of the CAR-T therapy&#x000a0;programs.<xref ref-type="bibr" rid="article-153034.r46">[46]</xref></p>
        <p>Caregiver support throughout the process of CAR-T and after is critical. The need for a 24-hour caregiver for at least four weeks and&#x000a0;staying close to the center after treatment should be emphasized.<xref ref-type="bibr" rid="article-153034.r76">[76]</xref>&#x000a0;Caregivers&#x000a0;should be included from the start, from&#x000a0;informed consenting to&#x000a0;teaching, clinic visit, and after discharge.</p>
      </sec>
      <sec id="article-153034.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Cancer immunotherapy has greatly advanced in recent years, with CAR-T cells emerging as an innovative technology that harnesses the immune system to combat&#x000a0;malignant diseases.&#x000a0;An interprofessional team is&#x000a0;needed to recognize and appropriately manage CAR-T AEs, including but not limited to neurology, critical care, and infectious diseases subspecialties. Most centers alert the neurology team for a neurological evaluation of the patient prior to the CAR-T administration.&#x000a0;Efforts should be aimed at providing accommodation to the patients traveling far from home for CAR-T and assisting with out-of-pocket costs.<xref ref-type="bibr" rid="article-153034.r77">[77]</xref></p>
        <p>Patient prerequisites that are fundamental for managing complications of HSCT post-discharge are also relevant to successful CAR-T, including socioeconomic and caregiver support and patient staying within a 1-hour transportation distance from the hospital for at least four weeks post-infusion.<xref ref-type="bibr" rid="article-153034.r46">[46]</xref>&#x000a0;Various centers have devised comprehensive protocols to monitor patients closely, ensure multidisciplinary coordination, and quick evaluation of the patients in either the clinic or ED&#x000a0;for any AEs, including fever, CRS, and ICANs.<xref ref-type="bibr" rid="article-153034.r47">[47]</xref><xref ref-type="bibr" rid="article-153034.r41">[41]</xref></p>
      </sec>
      <sec id="article-153034.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=153034&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=153034">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/cart-cell-therapy-toxicity/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=153034">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/153034/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=153034">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-153034.s15">
        <title>References</title>
        <ref id="article-153034.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sermer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Brentjens</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>CAR T-cell therapy: Full speed ahead.</article-title>
            <source>Hematol Oncol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>37 Suppl 1</volume>
            <fpage>95</fpage>
            <page-range>95-100</page-range>
            <pub-id pub-id-type="pmid">31187533</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Braendstrup</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Ruella</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19.</article-title>
            <source>Cytotherapy</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>57</fpage>
            <page-range>57-69</page-range>
            <pub-id pub-id-type="pmid">32014447</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kanapuru</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Bryan</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Pazdur</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Theoret</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma.</article-title>
            <source>Clin Cancer Res</source>
            <year>2022</year>
            <month>May</month>
            <day>02</day>
            <volume>28</volume>
            <issue>9</issue>
            <fpage>1759</fpage>
            <page-range>1759-1764</page-range>
            <pub-id pub-id-type="pmid">35046063</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chekol Abebe</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Yibeltal Shiferaw</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tadele Admasu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Asmamaw Dejenie</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma.</article-title>
            <source>Front Immunol</source>
            <year>2022</year>
            <volume>13</volume>
            <fpage>991092</fpage>
            <pub-id pub-id-type="pmid">36119032</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Safarzadeh Kozani</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Safarzadeh Kozani</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ahmadi Najafabadi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yousefi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mirarefin</surname>
                <given-names>SMJ</given-names>
              </name>
              <name>
                <surname>Rahbarizadeh</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?</article-title>
            <source>Front Immunol</source>
            <year>2022</year>
            <volume>13</volume>
            <fpage>795164</fpage>
            <pub-id pub-id-type="pmid">35634281</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <article-title>First-Ever CAR T-cell Therapy Approved in U.S.</article-title>
            <source>Cancer Discov</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>7</volume>
            <issue>10</issue>
            <fpage>OF1</fpage>
            <pub-id pub-id-type="pmid">28887358</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Si Lim</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Grupp</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>DiNofia</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Tisagenlecleucel for treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia.</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>68</volume>
            <issue>9</issue>
            <fpage>e29123</fpage>
            <pub-id pub-id-type="pmid">34061452</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <article-title>Tisagenlecleucel Is Safe and Effective in Relapsed/Refractory Follicular Lymphoma.</article-title>
            <source>Cancer Discov</source>
            <year>2022</year>
            <month>Mar</month>
            <day>01</day>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>OF4</fpage>
            <pub-id pub-id-type="pmid">34996779</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bouchkouj</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kasamon</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>de Claro</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Blumenthal</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Bryan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>McKee</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Pazdur</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma.</article-title>
            <source>Clin Cancer Res</source>
            <year>2019</year>
            <month>Mar</month>
            <day>15</day>
            <volume>25</volume>
            <issue>6</issue>
            <fpage>1702</fpage>
            <page-range>1702-1708</page-range>
            <pub-id pub-id-type="pmid">30413526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bouchkouj</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zimmerman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kasamon</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Theoret</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Purohit-Sheth</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma.</article-title>
            <source>Oncologist</source>
            <year>2022</year>
            <month>Jul</month>
            <day>05</day>
            <volume>27</volume>
            <issue>7</issue>
            <fpage>587</fpage>
            <page-range>587-594</page-range>
            <pub-id pub-id-type="pmid">35403693</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>St-Pierre</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>LI</given-names>
              </name>
            </person-group>
            <article-title>Lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma.</article-title>
            <source>Future Oncol</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>19</fpage>
            <page-range>19-28</page-range>
            <pub-id pub-id-type="pmid">36651471</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deshpande</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Munoz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma.</article-title>
            <source>Drugs Today (Barc)</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>58</volume>
            <issue>6</issue>
            <fpage>283</fpage>
            <page-range>283-298</page-range>
            <pub-id pub-id-type="pmid">35670706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Logue</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Peres</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Hashmi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Colin-Leitzinger</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Shrewsbury</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Hosoya</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Copponex</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kottra</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Hovanky</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sahaf</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Patil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lazaryan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Baluch</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Klinkova</surname>
                <given-names>OV</given-names>
              </name>
              <name>
                <surname>Bejanyan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Faramand</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Elmariah</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Khimani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Davila</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Mishra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Blue</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Grajales-Cruz</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Castaneda Puglianini</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Nishihori</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Brayer</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Shain</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Baz</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Locke</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Alsina</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sidana</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>DK</given-names>
              </name>
            </person-group>
            <article-title>Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma.</article-title>
            <source>Blood Adv</source>
            <year>2022</year>
            <month>Dec</month>
            <day>27</day>
            <volume>6</volume>
            <issue>24</issue>
            <fpage>6109</fpage>
            <page-range>6109-6119</page-range>
            <pub-id pub-id-type="pmid">35939783</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Albanyan</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Chavez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Munoz</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma.</article-title>
            <source>Ther Adv Hematol</source>
            <year>2022</year>
            <volume>13</volume>
            <fpage>20406207221141511</fpage>
            <pub-id pub-id-type="pmid">36505886</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mohty</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Moustafa</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Aljurf</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Murthy</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kharfan-Dabaja</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Emerging Role of Autologous CD19 CAR T-Cell Therapies in the Second-Line Setting for Large B-cell Lymphoma: A Game Changer?</article-title>
            <source>Hematol Oncol Stem Cell Ther</source>
            <year>2022</year>
            <month>Nov</month>
            <day>07</day>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>73</fpage>
            <page-range>73-80</page-range>
            <pub-id pub-id-type="pmid">36395495</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Teachey</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Lacey</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Melenhorst</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Maude</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Frey</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pequignot</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Finklestein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Barrett</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Fitzgerald</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Berg</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Aplenc</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Callahan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rheingold</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Rose-John</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Nazimuddin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wertheim</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>June</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Grupp</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.</article-title>
            <source>Cancer Discov</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>6</volume>
            <issue>6</issue>
            <fpage>664</fpage>
            <page-range>664-79</page-range>
            <pub-id pub-id-type="pmid">27076371</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gauthier</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Turtle</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.</article-title>
            <source>Curr Res Transl Med</source>
            <year>2018</year>
            <month>May</month>
            <volume>66</volume>
            <issue>2</issue>
            <fpage>50</fpage>
            <page-range>50-52</page-range>
            <pub-id pub-id-type="pmid">29625831</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taraseviciute</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tkachev</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ponce</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Turtle</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Snyder</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Liggitt</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Myerson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gonzalez-Cuyar</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Baldessari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>English</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Furlan</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Hoglund</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Finney</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Brakke</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Blazar</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Riddell</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Gardner</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kean</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates.</article-title>
            <source>Cancer Discov</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>8</volume>
            <issue>6</issue>
            <fpage>750</fpage>
            <page-range>750-763</page-range>
            <pub-id pub-id-type="pmid">29563103</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gust</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hay</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Hanafi</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Myerson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gonzalez-Cuyar</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Yeung</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Liles</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Wurfel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lopez</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Harju-Baker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>&#x000d6;zpolat</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fink</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Riddell</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Maloney</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Turtle</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.</article-title>
            <source>Cancer Discov</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>7</volume>
            <issue>12</issue>
            <fpage>1404</fpage>
            <page-range>1404-1419</page-range>
            <pub-id pub-id-type="pmid">29025771</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dotti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gottschalk</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Savoldo</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Brenner</surname>
                <given-names>MK</given-names>
              </name>
            </person-group>
            <article-title>Design and development of therapies using chimeric antigen receptor-expressing T cells.</article-title>
            <source>Immunol Rev</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>257</volume>
            <issue>1</issue>
            <fpage>107</fpage>
            <page-range>107-26</page-range>
            <pub-id pub-id-type="pmid">24329793</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van der Stegen</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Hamieh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sadelain</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The pharmacology of second-generation chimeric antigen receptors.</article-title>
            <source>Nat Rev Drug Discov</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>14</volume>
            <issue>7</issue>
            <fpage>499</fpage>
            <page-range>499-509</page-range>
            <pub-id pub-id-type="pmid">26129802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhao</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Condomines</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van der Stegen</surname>
                <given-names>SJC</given-names>
              </name>
              <name>
                <surname>Perna</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kloss</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Gunset</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Plotkin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sadelain</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells.</article-title>
            <source>Cancer Cell</source>
            <year>2015</year>
            <month>Oct</month>
            <day>12</day>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>415</fpage>
            <page-range>415-428</page-range>
            <pub-id pub-id-type="pmid">26461090</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Manz</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Bekelman</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Innovation and Access at the Mercy of Payment Policy: The Future of Chimeric Antigen Receptor Therapies.</article-title>
            <source>J Clin Oncol</source>
            <year>2020</year>
            <month>Feb</month>
            <day>10</day>
            <volume>38</volume>
            <issue>5</issue>
            <fpage>384</fpage>
            <page-range>384-387</page-range>
            <pub-id pub-id-type="pmid">31675247</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abramson</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Arnason</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Johnston</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Glass</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bachanova</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ibrahimi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mielke</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mutsaers</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hernandez-Ilizaliturri</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Izutsu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Morschhauser</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lunning</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Crotta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Montheard</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Previtali</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ogasawara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kamdar</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study.</article-title>
            <source>Blood</source>
            <year>2023</year>
            <month>Apr</month>
            <day>06</day>
            <volume>141</volume>
            <issue>14</issue>
            <fpage>1675</fpage>
            <page-range>1675-1684</page-range>
            <pub-id pub-id-type="pmid">36542826</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xiao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies.</article-title>
            <source>J Exp Clin Cancer Res</source>
            <year>2021</year>
            <month>Nov</month>
            <day>18</day>
            <volume>40</volume>
            <issue>1</issue>
            <fpage>367</fpage>
            <pub-id pub-id-type="pmid">34794490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Owusu</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Schiffer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Perreault</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Chimeric Antigen Receptor T Cells: Toxicity and Management Considerations.</article-title>
            <source>AACN Adv Crit Care</source>
            <year>2022</year>
            <month>Dec</month>
            <day>15</day>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>301</fpage>
            <page-range>301-307</page-range>
            <pub-id pub-id-type="pmid">36477845</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frey</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy.</article-title>
            <source>Biol Blood Marrow Transplant</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>e123</fpage>
            <page-range>e123-e127</page-range>
            <pub-id pub-id-type="pmid">30586620</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Santomasso</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Locke</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Ghobadi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Turtle</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Brudno</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Maus</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Mead</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pavletic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Go</surname>
                <given-names>WY</given-names>
              </name>
              <name>
                <surname>Eldjerou</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gardner</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Frey</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Curran</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Peggs</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pasquini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>DiPersio</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>van den Brink</surname>
                <given-names>MRM</given-names>
              </name>
              <name>
                <surname>Komanduri</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Grupp</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Neelapu</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.</article-title>
            <source>Biol Blood Marrow Transplant</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>625</fpage>
            <page-range>625-638</page-range>
            <pub-id pub-id-type="pmid">30592986</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holtzman</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bentzen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kesari</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bukhari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>El Chaer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lutfi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Siglin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hutnick</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gahres</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ruehle</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shanholtz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kocoglu</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Badros</surname>
                <given-names>AZ</given-names>
              </name>
              <name>
                <surname>Yared</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Hardy</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Rapoport</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Dahiya</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes.</article-title>
            <source>Neuro Oncol</source>
            <year>2021</year>
            <month>Jan</month>
            <day>30</day>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>112</fpage>
            <page-range>112-121</page-range>
            <pub-id pub-id-type="pmid">32750704</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hayden</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Roddie</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bader</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Basak</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Bonig</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bonini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chabannon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ciceri</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Corbacioglu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ellard</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sanchez-Guijo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>J&#x000e4;ger</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Hildebrandt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hudecek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kersten</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>K&#x000f6;hl</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kuball</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mielke</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mohty</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nagler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rees</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rioufol</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Saccardi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Snowden</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Styczynski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Subklewe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thieblemont</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Topp</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ispizua</surname>
                <given-names>&#x000c1;U</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vrhovac</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gribben</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Kr&#x000f6;ger</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Einsele</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yakoub-Agha</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA).</article-title>
            <source>Ann Oncol</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>33</volume>
            <issue>3</issue>
            <fpage>259</fpage>
            <page-range>259-275</page-range>
            <pub-id pub-id-type="pmid">34923107</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Reagan</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Liesveld</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Cytopenia after CAR-T Cell Therapy-A Brief Review of a Complex Problem.</article-title>
            <source>Cancers (Basel)</source>
            <year>2022</year>
            <month>Mar</month>
            <day>15</day>
            <volume>14</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">35326654</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xia</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors.</article-title>
            <source>Ann Med</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>54</volume>
            <issue>1</issue>
            <fpage>2951</fpage>
            <page-range>2951-2965</page-range>
            <pub-id pub-id-type="pmid">36382675</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Zu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Meng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lyu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Risk factors of tumor lysis syndrome in relapsed/refractory multiple myeloma patients undergoing BCMA CAR-T cell therapy.</article-title>
            <source>Zhejiang Da Xue Xue Bao Yi Xue Ban</source>
            <year>2022</year>
            <month>Apr</month>
            <day>25</day>
            <volume>51</volume>
            <issue>2</issue>
            <fpage>144</fpage>
            <page-range>144-150</page-range>
            <pub-id pub-id-type="pmid">36161293</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kochenderfer</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Dudley</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Carpenter</surname>
                <given-names>RO</given-names>
              </name>
              <name>
                <surname>Kassim</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Telford</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Hakim</surname>
                <given-names>FT</given-names>
              </name>
              <name>
                <surname>Halverson</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Fowler</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Hardy</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Mato</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Hickstein</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Gea-Banacloche</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Pavletic</surname>
                <given-names>SZ</given-names>
              </name>
              <name>
                <surname>Sportes</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Maric</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Wilder</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Blacklock-Schuver</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jena</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bishop</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Gress</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.</article-title>
            <source>Blood</source>
            <year>2013</year>
            <month>Dec</month>
            <day>12</day>
            <volume>122</volume>
            <issue>25</issue>
            <fpage>4129</fpage>
            <page-range>4129-39</page-range>
            <pub-id pub-id-type="pmid">24055823</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Ren</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Reactions Related to CAR-T Cell Therapy.</article-title>
            <source>Front Immunol</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>663201</fpage>
            <pub-id pub-id-type="pmid">33995389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davila</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Kloss</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Gunset</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sadelain</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia.</article-title>
            <source>PLoS One</source>
            <year>2013</year>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>e61338</fpage>
            <pub-id pub-id-type="pmid">23585892</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kochenderfer</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Janik</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Dudley</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Stetler-Stevenson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Maric</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Raffeld</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nathan</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Lanier</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.</article-title>
            <source>Blood</source>
            <year>2010</year>
            <month>Nov</month>
            <day>18</day>
            <volume>116</volume>
            <issue>20</issue>
            <fpage>4099</fpage>
            <page-range>4099-102</page-range>
            <pub-id pub-id-type="pmid">20668228</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Doan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pulsipher</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Hypogammaglobulinemia due to CAR T-cell therapy.</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>65</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">29230962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Rivi&#x000e8;re</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gonen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>S&#x000e9;n&#x000e9;chal</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Curran</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Sauter</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Santomasso</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mead</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Roshal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maslak</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Davila</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brentjens</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Sadelain</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Feb</month>
            <day>01</day>
            <volume>378</volume>
            <issue>5</issue>
            <fpage>449</fpage>
            <page-range>449-459</page-range>
            <pub-id pub-id-type="pmid">29385376</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carpenito</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Milone</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Hassan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Simonet</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Lakhal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Suhoski</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Varela-Rohena</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Haines</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Heitjan</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Albelda</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Riley</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Pastan</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>June</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>2009</year>
            <month>Mar</month>
            <day>03</day>
            <volume>106</volume>
            <issue>9</issue>
            <fpage>3360</fpage>
            <page-range>3360-5</page-range>
            <pub-id pub-id-type="pmid">19211796</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Neelapu</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Tummala</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kebriaei</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wierda</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Gutierrez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Locke</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Komanduri</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Daver</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Westin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gulbis</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Loghin</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>de Groot</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Adkins</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Rezvani</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hwu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Shpall</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.</article-title>
            <source>Nat Rev Clin Oncol</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>47</fpage>
            <page-range>47-62</page-range>
            <pub-id pub-id-type="pmid">28925994</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>G&#x000f6;del</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sieg</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Heger</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Kutsch</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Herling</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>B&#x000e4;rmann</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Scheid</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Borchmann</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Holtick</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Hematologic Rescue of CAR T-cell-mediated Prolonged Pancytopenia Using Autologous Peripheral Blood Hematopoietic Stem Cells in a Lymphoma Patient.</article-title>
            <source>Hemasphere</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>e545</fpage>
            <pub-id pub-id-type="pmid">33623885</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pathak</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bociek</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Vose</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Armitage</surname>
                <given-names>JO</given-names>
              </name>
            </person-group>
            <article-title>Risk of Second Primary Malignancies in Patients With Follicular Lymphoma: A United States Population-based Study.</article-title>
            <source>Clin Lymphoma Myeloma Leuk</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>17</volume>
            <issue>9</issue>
            <fpage>569</fpage>
            <page-range>569-574</page-range>
            <pub-id pub-id-type="pmid">28709798</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brudno</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Somerville</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Halverson</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Fowler</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Gea-Banacloche</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Pavletic</surname>
                <given-names>SZ</given-names>
              </name>
              <name>
                <surname>Hickstein</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Iwamoto</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Kurlander</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Maric</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Goy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Wilder</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Blacklock-Schuver</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hakim</surname>
                <given-names>FT</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Gress</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Kochenderfer</surname>
                <given-names>JN</given-names>
              </name>
            </person-group>
            <article-title>Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.</article-title>
            <source>J Clin Oncol</source>
            <year>2016</year>
            <month>Apr</month>
            <day>01</day>
            <volume>34</volume>
            <issue>10</issue>
            <fpage>1112</fpage>
            <page-range>1112-21</page-range>
            <pub-id pub-id-type="pmid">26811520</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bouchkouj</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Przepiorka</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Purohit-Sheth</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Theoret</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>FDA Approval Summary: Brexucabtagene Autoleucel for Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.</article-title>
            <source>Oncologist</source>
            <year>2022</year>
            <month>Oct</month>
            <day>01</day>
            <volume>27</volume>
            <issue>10</issue>
            <fpage>892</fpage>
            <page-range>892-899</page-range>
            <pub-id pub-id-type="pmid">35983953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taylor</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Reese</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Building a Program: Implications for Infrastructure, Nursing Education, and Training for CAR T-Cell Therapy.</article-title>
            <source>Clin J Oncol Nurs</source>
            <year>2019</year>
            <month>Apr</month>
            <day>01</day>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>20</fpage>
            <page-range>20-26</page-range>
            <pub-id pub-id-type="pmid">30880820</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marzal-Alfaro</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Escudero-Vilaplana</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Revuelta-Herrero</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Collado-Borrell</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Herranz-Alonso</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sanjurjo-Saez</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Chimeric Antigen Receptor T Cell Therapy Management and Safety: A Practical Tool From a Multidisciplinary Team Perspective.</article-title>
            <source>Front Oncol</source>
            <year>2021</year>
            <volume>11</volume>
            <fpage>636068</fpage>
            <pub-id pub-id-type="pmid">33777790</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Y&#x000e1;&#x000f1;ez</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez-Escamilla</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Perales</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>CAR T Cell Toxicity: Current Management and Future Directions.</article-title>
            <source>Hemasphere</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>3</volume>
            <issue>2</issue>
            <fpage>e186</fpage>
            <pub-id pub-id-type="pmid">31723825</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Y&#x000e1;&#x000f1;ez</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Alarc&#x000f3;n</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez-Escamilla</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Perales</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>How I treat adverse effects of CAR-T cell therapy.</article-title>
            <source>ESMO Open</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>4</volume>
            <issue>Suppl 4</issue>
            <fpage>e000746</fpage>
            <pub-id pub-id-type="pmid">32839196</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chou</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Turtle</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy.</article-title>
            <source>Expert Opin Biol Ther</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>20</volume>
            <issue>6</issue>
            <fpage>653</fpage>
            <page-range>653-664</page-range>
            <pub-id pub-id-type="pmid">32067497</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Gardner</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Louis</surname>
                <given-names>CU</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grupp</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Mackall</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Current concepts in the diagnosis and management of cytokine release syndrome.</article-title>
            <source>Blood</source>
            <year>2014</year>
            <month>Jul</month>
            <day>10</day>
            <volume>124</volume>
            <issue>2</issue>
            <fpage>188</fpage>
            <page-range>188-95</page-range>
            <pub-id pub-id-type="pmid">24876563</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brudno</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Kochenderfer</surname>
                <given-names>JN</given-names>
              </name>
            </person-group>
            <article-title>Toxicities of chimeric antigen receptor T cells: recognition and management.</article-title>
            <source>Blood</source>
            <year>2016</year>
            <month>Jun</month>
            <day>30</day>
            <volume>127</volume>
            <issue>26</issue>
            <fpage>3321</fpage>
            <page-range>3321-30</page-range>
            <pub-id pub-id-type="pmid">27207799</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murthy</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Yassine</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Iqbal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alotaibi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moustafa</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kharfan-Dabaja</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Management of CAR T-cell Related Toxicities: What did the Learning Curve Teach us so Far?</article-title>
            <source>Hematol Oncol Stem Cell Ther</source>
            <year>2022</year>
            <month>Nov</month>
            <day>07</day>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>100</fpage>
            <page-range>100-111</page-range>
            <pub-id pub-id-type="pmid">36395496</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maus</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bishop</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Brudno</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Callahan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Davila</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Diamonte</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dietrich</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fitzgerald</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Frigault</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Fry</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Holter-Chakrabarty</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Komanduri</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Locke</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Maude</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>McCarthy</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Mead</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Neelapu</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Neilan</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Santomasso</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Shpall</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Teachey</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Turtle</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Whitehead</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Grupp</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events.</article-title>
            <source>J Immunother Cancer</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>8</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">33335028</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Booth</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Kusoski</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Kennerly-Shah</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>The pharmacist's role in chimeric antigen receptor T cell therapy.</article-title>
            <source>J Oncol Pharm Pract</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>26</volume>
            <issue>7</issue>
            <fpage>1725</fpage>
            <page-range>1725-1731</page-range>
            <pub-id pub-id-type="pmid">32819199</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haseeb</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tholouli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Chimeric antigen receptor T-cell therapy in adults: management of toxicities and implications for critical care.</article-title>
            <source>BJA Educ</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>22</volume>
            <issue>9</issue>
            <fpage>330</fpage>
            <page-range>330-333</page-range>
            <pub-id pub-id-type="pmid">36033934</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alexander</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Culos</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Roddy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Bachmeier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Shigle</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Mahmoudjafari</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Chimeric Antigen Receptor T Cell Therapy: A Comprehensive Review of Clinical Efficacy, Toxicity, and Best Practices for Outpatient Administration.</article-title>
            <source>Transplant Cell Ther</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>27</volume>
            <issue>7</issue>
            <fpage>558</fpage>
            <page-range>558-570</page-range>
            <pub-id pub-id-type="pmid">33910041</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Acharya</surname>
                <given-names>UH</given-names>
              </name>
              <name>
                <surname>Dhawale</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yun</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jacobson</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Chavez</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Ramos</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Appelbaum</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Maloney</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.</article-title>
            <source>Expert Rev Hematol</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>195</fpage>
            <page-range>195-205</page-range>
            <pub-id pub-id-type="pmid">30793644</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Porter</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Frey</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Weng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Grupp</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel.</article-title>
            <source>J Hematol Oncol</source>
            <year>2018</year>
            <month>Mar</month>
            <day>02</day>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>35</fpage>
            <pub-id pub-id-type="pmid">29499750</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garbers</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Heink</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Korn</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rose-John</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Interleukin-6: designing specific therapeutics for a complex cytokine.</article-title>
            <source>Nat Rev Drug Discov</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>17</volume>
            <issue>6</issue>
            <fpage>395</fpage>
            <page-range>395-412</page-range>
            <pub-id pub-id-type="pmid">29725131</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strati</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kebriaei</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nastoupil</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Claussen</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Horowitz</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>ART</given-names>
              </name>
              <name>
                <surname>Do</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Nair</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shpall</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Neelapu</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Westin</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma.</article-title>
            <source>Blood Adv</source>
            <year>2020</year>
            <month>Jul</month>
            <day>14</day>
            <volume>4</volume>
            <issue>13</issue>
            <fpage>3123</fpage>
            <page-range>3123-3127</page-range>
            <pub-id pub-id-type="pmid">32645136</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lipe</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Renaud</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Siltuximab as a primary treatment for cytokine release syndrome in a patient receiving a bispecific antibody in a clinical trial setting.</article-title>
            <source>J Oncol Pharm Pract</source>
            <year>2023</year>
            <month>Jun</month>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>1006</fpage>
            <page-range>1006-1010</page-range>
            <pub-id pub-id-type="pmid">36464766</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jain</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Locke</surname>
                <given-names>FL</given-names>
              </name>
            </person-group>
            <article-title>How I treat cytopenias after CAR T-cell therapy.</article-title>
            <source>Blood</source>
            <year>2023</year>
            <month>May</month>
            <day>18</day>
            <volume>141</volume>
            <issue>20</issue>
            <fpage>2460</fpage>
            <page-range>2460-2469</page-range>
            <pub-id pub-id-type="pmid">36800563</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schuster</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Svoboda</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chong</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Nasta</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Mato</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Anak</surname>
                <given-names>&#x000d6;</given-names>
              </name>
              <name>
                <surname>Brogdon</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Pruteanu-Malinici</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bhoj</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Landsburg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wasik</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Lacey</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Melenhorst</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>June</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.</article-title>
            <source>N Engl J Med</source>
            <year>2017</year>
            <month>Dec</month>
            <day>28</day>
            <volume>377</volume>
            <issue>26</issue>
            <fpage>2545</fpage>
            <page-range>2545-2554</page-range>
            <pub-id pub-id-type="pmid">29226764</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hernani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Benzaqu&#x000e9;n</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Solano</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Toxicities following CAR-T therapy for hematological malignancies.</article-title>
            <source>Cancer Treat Rev</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>111</volume>
            <fpage>102479</fpage>
            <pub-id pub-id-type="pmid">36308910</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maude</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Frey</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Aplenc</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Barrett</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Bunin</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Chew</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Lacey</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Mahnke</surname>
                <given-names>YD</given-names>
              </name>
              <name>
                <surname>Melenhorst</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Rheingold</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Teachey</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>June</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Grupp</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Chimeric antigen receptor T cells for sustained remissions in leukemia.</article-title>
            <source>N Engl J Med</source>
            <year>2014</year>
            <month>Oct</month>
            <day>16</day>
            <volume>371</volume>
            <issue>16</issue>
            <fpage>1507</fpage>
            <page-range>1507-17</page-range>
            <pub-id pub-id-type="pmid">25317870</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Clinical features of hemophagocytic syndrome following BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma.</article-title>
            <source>Zhejiang Da Xue Xue Bao Yi Xue Ban</source>
            <year>2022</year>
            <month>Apr</month>
            <day>25</day>
            <volume>51</volume>
            <issue>2</issue>
            <fpage>160</fpage>
            <page-range>160-166</page-range>
            <pub-id pub-id-type="pmid">36161295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sievers</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Johncy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Adkins</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Recognizing and Grading CAR T-Cell Toxicities: An Advanced Practitioner Perspective.</article-title>
            <source>Front Oncol</source>
            <year>2020</year>
            <volume>10</volume>
            <fpage>885</fpage>
            <pub-id pub-id-type="pmid">32670871</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maus</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Haas</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Beatty</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Albelda</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kalos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>June</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.</article-title>
            <source>Cancer Immunol Res</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>26</fpage>
            <page-range>26-31</page-range>
            <pub-id pub-id-type="pmid">24777247</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hashmi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bachmeier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chavez</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hussaini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Krivenko</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nishihori</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kotani</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Davila</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Locke</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy.</article-title>
            <source>Br J Haematol</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>187</volume>
            <issue>2</issue>
            <fpage>e35</fpage>
            <page-range>e35-e38</page-range>
            <pub-id pub-id-type="pmid">31410842</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Howard</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Pui</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>The tumor lysis syndrome.</article-title>
            <source>N Engl J Med</source>
            <year>2011</year>
            <month>May</month>
            <day>12</day>
            <volume>364</volume>
            <issue>19</issue>
            <fpage>1844</fpage>
            <page-range>1844-54</page-range>
            <pub-id pub-id-type="pmid">21561350</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Messmer</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Que</surname>
                <given-names>YA</given-names>
              </name>
              <name>
                <surname>Schankin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Banz</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Bacher</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Novak</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Pabst</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>CAR T-cell therapy and critical care : A&#x000a0;survival guide for medical emergency teams.</article-title>
            <source>Wien Klin Wochenschr</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>133</volume>
            <issue>23-24</issue>
            <fpage>1318</fpage>
            <page-range>1318-1325</page-range>
            <pub-id pub-id-type="pmid">34613477</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tallantyre</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Parry-Jones</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>MPG</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Ingram</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Neurological updates: neurological complications of CAR-T therapy.</article-title>
            <source>J Neurol</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>268</volume>
            <issue>4</issue>
            <fpage>1544</fpage>
            <page-range>1544-1554</page-range>
            <pub-id pub-id-type="pmid">33140239</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hunter</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Jacobson</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>CAR T-Cell Associated Neurotoxicity: Mechanisms, Clinicopathologic Correlates, and Future Directions.</article-title>
            <source>J Natl Cancer Inst</source>
            <year>2019</year>
            <month>Jul</month>
            <day>01</day>
            <volume>111</volume>
            <issue>7</issue>
            <fpage>646</fpage>
            <page-range>646-654</page-range>
            <pub-id pub-id-type="pmid">30753567</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ruark</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mullane</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cleary</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cordeiro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bezerra</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Voutsinas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Flynn</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Turtle</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Maloney</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Fann</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Bar</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy.</article-title>
            <source>Biol Blood Marrow Transplant</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>34</fpage>
            <page-range>34-43</page-range>
            <pub-id pub-id-type="pmid">31605820</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perica</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Curran</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Brentjens</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Giralt</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center.</article-title>
            <source>Biol Blood Marrow Transplant</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>24</volume>
            <issue>6</issue>
            <fpage>1135</fpage>
            <page-range>1135-1141</page-range>
            <pub-id pub-id-type="pmid">29499327</pub-id>
          </element-citation>
        </ref>
        <ref id="article-153034.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hernandez</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Prasad</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gellad</surname>
                <given-names>WF</given-names>
              </name>
            </person-group>
            <article-title>Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy.</article-title>
            <source>JAMA Oncol</source>
            <year>2018</year>
            <month>Jul</month>
            <day>01</day>
            <volume>4</volume>
            <issue>7</issue>
            <fpage>994</fpage>
            <page-range>994-996</page-range>
            <pub-id pub-id-type="pmid">29710129</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
